Risk factors for lipodystrophy in the CISAI cohort

Biomedicine and Pharmacotherapy

Volumn 57, Issue 9, 2003, Pages 422-427

  Bonfanti, Paolo ^a   Gulisano, Cecilia ^a   Ricci, Elena ^b   Timillero, Lia ^c   Valsecchi, Laura ^a   Carradori, Silvia ^d   Pusterla, Luigi ^e   Fortuna, Paolo ^f   Miccolis, Sebastiano ^g   Magnani, Carlo ^h   Gabbuti, Andrea ⁱ   Parazzini, Fabio ^b   Martinelli, Canio ^j   Faggion, Ivano ^a   Landonio, Simona ^a   Quirino, Tiziana ^a   Vigevani, GianMarco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d S ANNA HOSPITAL   (Italy)

^e SANT ANNA HOSPITAL   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g CARLO POMA HOSPITAL   (Italy)

^h Ospedale di Cuggiono   (Italy)

ⁱ SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Adverse reactions; Antiretroviral therapy; Lipodystrophy; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; FOLLOW UP; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT INFORMATION; PHYSICIAN; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SEX RATIO;

EID: 0344256537     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.06.002     Document Type: Article

References (44)

1. Hogg R.S., Heath K.V., Yip B., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Assoc. 279:1998;450-454.
2. Palella F.J. Jr, Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med. 338:1998;853-860.
3. Lo J.C., Mulligan K., Tai V.W., et al. Buffalo hump in men with HIV-1 infection. Lancet. 351:1998;867-870.
4. Lo J.C., Mulligan K., Tai V.W., et al. Body shape changes in HIV-infected patients. J Acquired Immune Defic Syndromes. 19:1998;307-308.
5. Dong K.L., Baussermann L.L., Flynn M.M., et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on HAART. J Acquired Immune Defic Syndromes. 21:1999;107-113.
6. Gervasoni C., Ridolfo A., Trifiro G., et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 13:1999;465-471.
7. Miller K.D., Jones E., Yanowsky J.A., et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 351:1998;871-875.
8. Carr A., Miller J., Law M., Cooper D. A syndrome of lipoatrophy, lactic acidemia, and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 14:2000;F25-F32.
9. Engelson E.S., Kotler D.P., Tan Y., et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr. 69:1999;1162-1169.
10. Kotler D.P., Rosenbaum K., Wang J., Pierson R.N. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquired Immune Defic Syndromes. 20:1999;228-237.
11. Madge S., Kinloch de Loes S., Mercey D., et al. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS. 13:1999;735-737.
12. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIB protease inhibitors. AIDS. 12:1998;F51-E58.
13. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 353:1999;2093-2099.
14. Saint Marc T., Partisani M., Poizot Martin I., et al. A syndrome of peripheral fat wasting in patients receiving long-term nucleoside analogue therapy. AIDS. 13:1999;1659-1667.
15. Martinez E., Mocroft A., Garcia Viejo M., et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 357:2001;592-598.
16. Wanke C.A. Epidemiological and clinical aspects of the metabolic complications of HIV infection: the fat redistribution syndrome. AIDS. 13:1999;1287-1293.
17. Reus S., Arroyo E., Boix V., Portilla J. Lipodystrophy and hyperglycemia produced by protease inhibitors. Ann Med Interne. 17:2000;123-126.
18. Bonfanti P., Valsecchi L., Parazzini F., et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquired Immune Defic Syndromes. 23:2000;236-245.
19. Schwenk A. Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Opin Infect Dis. 15:2002;9-16.
20. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187-220.
21. Galli M., Cozzi-Lepri A., Ridolfo A. Incidence of adipose tissue alterations in first-line antiretroviral therapy. Arch Intern Med. 162:2002;2621-2628.
22. Rokotoambinina B., Medioni J., Rabian C., et al. Lipodystrophic syndromes and hyperlipidemia in cohort of HIV-1 infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquired Immune Defic Syndromes. 27:(5):2001;443-449.
23. Bernasconi E., Boubaker K., Junghans C., et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs. J Acquired Immune Defic Syndromes. 31:2002;50-55.
24. Heath K.V., Hogg R., Singer J., et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquired Immune Defic Syndromes. 30:2002;440-447.
25. Lichtenstein K.A., Ward D.J., Moorman A.C., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 15:2001;1389-1398.
26. Tsidras S., Mantzoros C., Hammer S., et al. Effect of protease inhibitors on hyperglycemia, and lipodystropy: a 5-year cohort study. Arch Intern Med. 160:(13):2000;2050-2053.
27. Viraben R., Aquilina C. Indinavir-associated lipodystrophy. AIDS. 12:(6):1998;F37-F39.
28. Dreezen C., Schrooten W., De Mey I., et al. Self-reported signs of lipodystrophy by persons living with HIV infection. Int J Std AIDS. 13:2002;393-398.
29. Benson J.O., McGhee K., Coplan P. Fat redistribution in indinavir-treated with HIV infection: a review of postmarketing cases. J Acquired Immune Defic Syndromes. 25:2000;130-139.
30. Miller D., Jones E., Yanoski J.A., et al. Visceral abdominal fat accumulation associated with use of indinavir. Lancet. 351:1998;871-875.
31. Hadigan C., Meigs J.B., Corcoran C., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 32:2001;130-139.
32. Hadigan C., Miller K., Corcoran C., et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected woman. J Clin Endocrin Metab. 84:1999;1932-1937.
33. Lopes J., Engelson E.S., Wang J., et al. Interaction among sex, HIV infection and fat redistribution. AIDS Read. 10:(10):2000;589-594.
34. Mallal S., John M., Moore C., et al. Contribution of nucleoside analogue reverse trascriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 14:2000;1309-1316.
35. Saint Marc T., Partisani M., Poizot M., et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO Study. AIDS. 14:2000;37-49.
36. Galli M., Veglia F., Angarano G., et al. Risk factor associated with types of metabolic and morphological alterations according to the Marrakesh classification. Program and abstract of the 2nd international workshop on adverse drug reactions and lipodystrophy in HIV. Toronto, Canada:2000;. [Abstract P61].
37. Boufassa F., Dulioust A., Lascaux A.S., et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials. 2:2001;339-345.
38. Martinez E., Mocroft A., Garcia-Viejo M.A., et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 357:2001;592-598.
39. Mina J., David N., Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther. 6:2001;9-20.
40. Mallon P.W., Cooper D.A., Carr A. HIV-associated lipodystrophy. HIV Med. 2:2001;166-173.
41. Van der Valk M., Gisolf E.H., Reiss P., et al. Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 15:2001;847-855.
42. Mauss S., Corzillius M., Wolf E., et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med. 3:2002;49-55.
43. Heath K.V., Hogg R.S., Chan K.J., et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 15:2001;271-273.
44. Bogner J.R., Vielhauer V., Beckmann R.A., et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquired Immune Defic Syndromes. 27:2001;237-244.